Notice of Proposed Sale · 144
Monte Rosa Therapeutics, Inc.
GLUENASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Monte Rosa Therapeutics, Inc.
- Issuer CIK
- 0001826457
- SEC file number
- 001-40522
- Phone
- 617-949-2643
- Person for whose account securities are to be sold
- Champoux Jennifer
- Relationships to issuer
- Officer
- Street
- 321 HARRISON AVENUE
- Street (continued)
- SUITE 900
- City
- BOSTON
- State / country code
- MA
- Postal code
- 02118
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 4,351 | 101,729.86 | 84,479,418 | 07/15/2026 | NASDAQ | UBS Financial Services, Inc. |
Broker / market maker — proposed row 1, entry 1
- Name
- UBS Financial Services, Inc.
- Street
- 11 Madison Ave
- Street (continued)
- 4th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10010
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/15/2026 | Exercise of stock options | Issuer | 4,351 | N | 07/15/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Jennifer Champoux | Common | 05/22/2026 | 2,176 | 41,344.00 |
| Jennifer Champoux | Common | 05/27/2026 | 2,175 | 43,500.00 |
| Jennifer Champoux | Common | 06/17/2026 | 2,176 | 41,344.00 |
| Jennifer Champoux | Common | 06/23/2026 | 2,175 | 43,500.00 |
Seller — prior-sale row 1, entry 1
- Name
- Jennifer Champoux
- Street
- 321 HARRISON AVENUE
- Street (continued)
- SUITE 900
- City
- BOSTON
- State / country code
- MA
- Postal code
- 02118
Seller — prior-sale row 2, entry 1
- Name
- Jennifer Champoux
- Street
- 321 HARRISON AVENUE
- Street (continued)
- SUITE 900
- City
- BOSTON
- State / country code
- MA
- Postal code
- 02118
Seller — prior-sale row 3, entry 1
- Name
- Jennifer Champoux
- Street
- 321 HARRISON AVENUE
- Street (continued)
- SUITE 900
- City
- BOSTON
- State / country code
- MA
- Postal code
- 02118
Seller — prior-sale row 4, entry 1
- Name
- Jennifer Champoux
- Street
- 321 HARRISON AVENUE
- Street (continued)
- SUITE 900
- City
- BOSTON
- State / country code
- MA
- Postal code
- 02118
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 07/15/2026
- Signed
- /s/ UBS Financial Services Inc, as attorney-in-fact for Jennifer Champoux
- Plan adoption dates
- 02/19/2026
Company context
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology, and neurology. For more information, visit www.monterosatx.com.